|
|
![horizontal rule](https://webarchive.library.unt.edu/web/20090511194911im_/http://www.fda.gov/graphics/blkpixel.gif) |
Congressional
Testimony
|
|
![](https://webarchive.library.unt.edu/web/20090511194911im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
|
|
|
|
![](https://webarchive.library.unt.edu/web/20090511194911im_/http://www.fda.gov/graphics/dot_clear.gif) |
2000
October
- Jane E. Henney, M.D.,
October 3, 2000
Commissioner of Food and Drug Administration -- Before the
Subcommittee on Oversight and Investigations to discuss our
efforts to detect and prevent the introduction of counterfeit
bulk drugs into the drug supply of the United States (U.S.).
- Mark A. Elengold, October
3, 2000
Deputy Director, Operations, Center for Biologics Evaluation
and Research (CBER)/FDA -- Before the Committee on Government
Reform to discuss the Anthrax Vaccine Adsorbed and the opportunity
for FDA to update the Committee of the regulatory status of
BioPort Corporation (BioPort), and the Agency's experience
with adverse event reports for the anthrax vaccine
September
- Joseph A Levitt, Esq., September
20, 2000
Director of the Center for Food Safety and Applied Nutrition/FDA
-- Before the Committee on Agriculture, Nutrition, and Forestry,
United States Senate to discuss how our food safety system
should address microbial contamination.
- Jane E. Henney, M.D., September
20, 2000
Commissioner of Food and Drug Administration -- Before the
Subcommittee on Labor, Health and Human Services and Education
-- Committee of Appropriation to discuss issues related to
antimicrobial resistance and FDA's important role in addressing
this growing public health problem
July
- William Egan, Ph.D., July 18,
2000
Acting Director Office of Vaccine Research and Review (OVRR),
Center for Biologics Evaluation and Research (CBER), FDA --
Before the Committee on Government Reform to discuss the issue
of additives in childhood vaccines, in particular thimerosal.
- Kathryn C. Zoon, Ph.D.,
July 12, 2000
Director Center for Biologics Evaluation and Research, FDA
-- Before the Committee on Armed Services to discuss anthrax
vaccine and the opportunity for FDA to explain our role in
the pre-market review and post-market surveillance of regulated
products, and more specifically explain our role with respect
to the regulation of the Anthrax Vaccine, Adsorbed.
June
- David W. Feigal, M.D., June 27,
2000
Director Center for Devices and Radiological Health, FDA --
Before the Senate Committee on Health, Education, Labor and
Pensions to discuss the Agency's approach to the issue of
reuse of medical devices labeled for single-use.
- Linda Suydam, D.P.A., June 14,
2000
Senior Associate Commissioner, FDA -- Before the Committee
on Government Reform to discuss FDA's advisory committees.
- Dennis E. Baker, June
8, 2000
Associate Commissioner for Regulatory Affairs, FDA -- Before
the Subcommittee on Oversight and Investigations to discuss
the concerns about imported counterfeit bulk drugs and the
Agency's actions designed to protect the American public from
the possible risks that such drugs may pose.
- Richard Pazdur, M.D., June7,
2000
Director, Division of Oncology Drug Products, Center for Drug
Evaluation and Research (CDER) FDA -- Before the Committee
on Government Reform to ensure that new cancer drugs are as
safe and effective as possible and to facilitate access to
promising therapies for seriously ill and dying patients when
no other treatment is available.
May
- William K. Hubbard, May
25, 2000
Senior Associate Commisioner for Policy, Planning and Legislation,
FDA -- Before the Subcommittee on Oversight and Investigations
to discuss FDA's concern about the public health implications
of Internet drug sales.
- William F. Raub, Ph.D.,
May 25, 2000
Deputy Assistant Secretary for Science Policy for the Department
of Health and Human Services (HHS) -- Before the Subcommittee
on Public Health to discuss HHS efforts to protect human research
subjects throughout our programs and, in particular, to enhance
oversight of human gene transfer research.
- William F. Raub, Ph.D.,
May 3, 2000
Deputy Assistant Secretary for Science Policy for the Department
of Health and Human Services (HHS) -- Before the Subcommittee
on Criminal Justice to discuss HHS' efforts to protect human
research subjects.
March
- Jane E. Henney, M.D., March
21, 2000
Commissioner of Food and Drug Administration -- Before the
Committee on Health, Education, Labor and Pensions to discuss
with you the benefits and risks of pharmaceutical sales over
the Internet.
- Ronald Coene, March 15, 2000
Deputy Director for Washington Operations, National Center
for Toxicological Research (NCTR) -- Subcommittee on National
Security to discuss my role with the Ranch Hand Advisory Committee.
- Jane E. Henney, M.D., March
7, 2000
Commissioner of Food and Drug Administration -- Before the
U.S. Senate -- Committee on Appropriations to discuss the
proposed budget for fiscal year 2001.
February
- Jane E. Henney, M.D., February
29, 2000
Commissioner of Food and Drug Administration--Before the House
Subcommittee to discuss the proposed budget for fiscal year
2001.
- David Feigal, M.D., February 10,
2000
Director of the Center for Devices and Radiological Health
(CDRH) discuss the Agency's approach to the issue of reuse
of medical devices labeled for single-use.
- Jay P. Siegel, M.D., February
2, 2000
Director, Office of Therapeutics Research and Review, Center
for Biologics Evaluation and Research (CBER), Food and Drug
Administration to discuss gene therapy and the Federal government's
role in the oversight of this field of medical research.
- Janet Woodcock, M.D., February
1, 2000
Director, Center for Drug Evaluation and Research, Food and
Drug Administration before the Committee on Health, Education,
Labor and Pensions to discussion of drug related adverse events,
FDA's role in addressing these events, and what the Agency
is doing and can do to reduce their occurrence.
|
![](https://webarchive.library.unt.edu/web/20090511194911im_/http://www.fda.gov/graphics/dot_clear.gif) |
![](https://webarchive.library.unt.edu/web/20090511194911im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
![](https://webarchive.library.unt.edu/web/20090511194911im_/http://www.fda.gov/graphics/dot_clear.gif) |
![](https://webarchive.library.unt.edu/web/20090511194911im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
![](https://webarchive.library.unt.edu/web/20090511194911im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
![](https://webarchive.library.unt.edu/web/20090511194911im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
|
|